Roxro Pharma Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Roxro Pharma Inc.
Takeda Gets GI Candidate – And Possibly Company – In Altos Deal
In the latest in a string of deals, Takeda's agreement to acquire global rights to Altos's gastroparesis candidate - and possibly the company itself - gives the Japanese giant another asset in its core gastrointestinal area.
2011 Scrip Asia 100 - M&A Watch Asia
M&A Watch: Selected Asian M&A deals, March 2010 to March 2011
Intranasal ketorolac for pain launched in the US, by Daiichi Sankyo's Luitpold Pharma
Daiichi Sankyo's US subsidiary Luitpold Pharmaceuticals, through its newly established division known as Regency Therapeutics, has launched the non-steroidal anti-inflammatory drug (NSAID) ketorolac, Sprix (ketorolac tromethamine) nasal spray, for the short term (up to five days) management of moderate to moderately severe pain that requires opioid analgesia.
New appointments at Symphogen
Symphogen, a private Danish biopharmaceutical company developing antibody therapeutics to treat cancer, and infectious and autoimmune diseases, has appointed Dr Ivan Horak chief scientific officer and medical officer and Gayle Mills chief business officer. Dr Horak joins from Enzon, where he was most recently president of R&D, having been chief scientific officer since 2005. Ms Mills had served as executive vice-president of business operations and chief business officer at Roxro Pharma for the past five years until the company's acquisition by Luitpold Pharmaceuticals, a subsidiary of Daiichi Sankyo.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice